FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011195144> ?p ?o ?g. }

• W2011195144 endingPage "524" @default.
• W2011195144 startingPage "518" @default.
• W2011195144 abstract "Objective The conditionally replicative adenovirus Ad5/3-Δ24 has a type-3 knob incorporated into the type-5 fiber that facilitates enhanced ovarian cancer infectivity. Preclinical studies have shown that Ad5/3-Δ24 achieves significant oncolysis and anti-tumor activity in ovarian cancer models. The purpose of this study was to evaluate in a phase I trial the feasibility and safety of intraperitoneal (IP) Ad5/3-Δ24 in recurrent ovarian cancer patients. Methods Eligible patients were treated with IP Ad5/3-Δ24 for 3 consecutive days in one of three dose cohorts ranging 1 × 1010–1 × 1012 vp. Toxicity was assessed utilizing CTC grading and efficacy with RECIST. Ascites, serum, and other samples were obtained to evaluate gene transfer, generation of wildtype virus, viral shedding, and antibody response. Results Nine of 10 patients completed treatment per protocol. A total of 15 vector-related adverse events were experienced in 5 patients. These events included fever or chills, nausea, fatigue, and myalgia. All were grades 1–2 in nature, transient, and medically managed. Of the 8 treated patients evaluable for response, six patients had stable disease and 2 patients had progressive disease. Three patients had decreased CA-125 from pretreatment levels one month after treatment. Ancillary biologic studies indicated Ad5/3-Δ24 replication in patients in the higher dose cohorts. All patients experienced an anti-adenoviral neutralizing antibody effect. Conclusions This study suggests the feasibility and safety of a serotype chimeric infectivity-enhanced CRAd, Ad5/3-Δ24, as a potential therapeutic option for recurrent ovarian cancer patients." @default.
• W2011195144 created "2016-06-24" @default.
• W2011195144 creator A5004442337 @default.
• W2011195144 creator A5009816072 @default.
• W2011195144 creator A5017208495 @default.
• W2011195144 creator A5019160700 @default.
• W2011195144 creator A5022987623 @default.
• W2011195144 creator A5036159485 @default.
• W2011195144 creator A5040138737 @default.
• W2011195144 creator A5043999741 @default.
• W2011195144 creator A5069881830 @default.
• W2011195144 creator A5079520757 @default.
• W2011195144 creator A5083849374 @default.
• W2011195144 date "2013-09-01" @default.
• W2011195144 modified "2023-10-09" @default.
• W2011195144 title "A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer" @default.
• W2011195144 cites W1491631791 @default.
• W2011195144 cites W1531166036 @default.
• W2011195144 cites W1641036275 @default.
• W2011195144 cites W1978847370 @default.
• W2011195144 cites W2002710053 @default.
• W2011195144 cites W2010441567 @default.
• W2011195144 cites W2028042551 @default.
• W2011195144 cites W2030599987 @default.
• W2011195144 cites W2059250207 @default.
• W2011195144 cites W2063643192 @default.
• W2011195144 cites W2082600436 @default.
• W2011195144 cites W2085649860 @default.
• W2011195144 cites W2102807955 @default.
• W2011195144 cites W2108309692 @default.
• W2011195144 cites W2110592777 @default.
• W2011195144 cites W2113822184 @default.
• W2011195144 cites W2120235529 @default.
• W2011195144 cites W2121129806 @default.
• W2011195144 cites W2130941707 @default.
• W2011195144 cites W2136248391 @default.
• W2011195144 cites W2143113338 @default.
• W2011195144 cites W2144674318 @default.
• W2011195144 cites W2147630291 @default.
• W2011195144 cites W2147649350 @default.
• W2011195144 cites W2154175915 @default.
• W2011195144 cites W2156009518 @default.
• W2011195144 cites W2156383817 @default.
• W2011195144 cites W2165948908 @default.
• W2011195144 cites W2168595271 @default.
• W2011195144 cites W2242902452 @default.
• W2011195144 cites W2328421677 @default.
• W2011195144 cites W4243504731 @default.
• W2011195144 doi "https://doi.org/10.1016/j.ygyno.2013.06.003" @default.
• W2011195144 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3748258" @default.
• W2011195144 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23756180" @default.
• W2011195144 hasPublicationYear "2013" @default.
• W2011195144 type Work @default.
• W2011195144 sameAs 2011195144 @default.
• W2011195144 citedByCount "73" @default.
• W2011195144 countsByYear W20111951442014 @default.
• W2011195144 countsByYear W20111951442015 @default.
• W2011195144 countsByYear W20111951442016 @default.
• W2011195144 countsByYear W20111951442017 @default.
• W2011195144 countsByYear W20111951442018 @default.
• W2011195144 countsByYear W20111951442019 @default.
• W2011195144 countsByYear W20111951442020 @default.
• W2011195144 countsByYear W20111951442021 @default.
• W2011195144 countsByYear W20111951442022 @default.
• W2011195144 countsByYear W20111951442023 @default.
• W2011195144 crossrefType "journal-article" @default.
• W2011195144 hasAuthorship W2011195144A5004442337 @default.
• W2011195144 hasAuthorship W2011195144A5009816072 @default.
• W2011195144 hasAuthorship W2011195144A5017208495 @default.
• W2011195144 hasAuthorship W2011195144A5019160700 @default.
• W2011195144 hasAuthorship W2011195144A5022987623 @default.
• W2011195144 hasAuthorship W2011195144A5036159485 @default.
• W2011195144 hasAuthorship W2011195144A5040138737 @default.
• W2011195144 hasAuthorship W2011195144A5043999741 @default.
• W2011195144 hasAuthorship W2011195144A5069881830 @default.
• W2011195144 hasAuthorship W2011195144A5079520757 @default.
• W2011195144 hasAuthorship W2011195144A5083849374 @default.
• W2011195144 hasBestOaLocation W20111951442 @default.
• W2011195144 hasConcept C121608353 @default.
• W2011195144 hasConcept C126322002 @default.
• W2011195144 hasConcept C143998085 @default.
• W2011195144 hasConcept C197934379 @default.
• W2011195144 hasConcept C203014093 @default.
• W2011195144 hasConcept C2778594517 @default.
• W2011195144 hasConcept C2778616394 @default.
• W2011195144 hasConcept C2780427987 @default.
• W2011195144 hasConcept C2780496750 @default.
• W2011195144 hasConcept C31760486 @default.
• W2011195144 hasConcept C535046627 @default.
• W2011195144 hasConcept C71924100 @default.
• W2011195144 hasConcept C90924648 @default.
• W2011195144 hasConceptScore W2011195144C121608353 @default.
• W2011195144 hasConceptScore W2011195144C126322002 @default.
• W2011195144 hasConceptScore W2011195144C143998085 @default.
• W2011195144 hasConceptScore W2011195144C197934379 @default.
• W2011195144 hasConceptScore W2011195144C203014093 @default.
• W2011195144 hasConceptScore W2011195144C2778594517 @default.
• W2011195144 hasConceptScore W2011195144C2778616394 @default.

• next